Patents Assigned to Oregon Health and Science University
-
Patent number: 12050257Abstract: Methods, computer-readable storage devices, and systems are described for reducing movement of a patient undergoing a magnetic resonance imaging (MRI) scan by aligning MRI data, the method implemented on a Framewise Integrated Real-time MRI Monitoring (“FIRMM”) computing device including at least one processor in communication with at least one memory device. Aspects of the method comprise receiving a data frame from the MRI system, aligning the received data frame to a preceding data frame, calculating motion of a body part between the received data frame and the preceding data frame, calculating total frame displacement, and excluding data frames with a cutoff above a pre-identified threshold of the total frame displacement.Type: GrantFiled: December 2, 2022Date of Patent: July 30, 2024Assignees: Washington University, Oregon Health and Science UniversityInventors: Nico Dosenbach, Jonathan Koller, Andrew Van, Abraham Snyder, Amy Mirro, Damien Fair, Eric Earl, Rachel Klein, Oscar Miranda Dominguez, Anders Perrone
-
Patent number: 11932626Abstract: The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 13, 2022Date of Patent: March 19, 2024Assignees: Southern Research Institute, Oregon Health and Science UniversityInventors: Ashish Kumar Pathak, Corinne E. Augelli-Szafran, Atefeh Garzan, Daniel Steblow, Nicole Haese
-
Patent number: 11834669Abstract: Disclosed herein are cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: July 1, 2021Date of Patent: December 5, 2023Assignees: International AIDS Vaccine Initiative, Inc., Oregon Health and Science UniversityInventors: Thomas G. Evans, Ravi Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
-
Patent number: 11578073Abstract: The present disclosure is concerned with xanthine analogs, methods of making xanthine analogs, and methods of treating West Nile virus using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: June 18, 2020Date of Patent: February 14, 2023Assignees: Southern Research Institute, Oregon Health and Science UniversityInventors: Ashish Kumar Pathak, Theresa Ha Nguyen, Corinne E. Augelli-Szafran, Alec Jay Hirsch, Jessica Lee Smith
-
Patent number: 11566019Abstract: The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: April 2, 2021Date of Patent: January 31, 2023Assignees: Southern Research Institute, Oregon Health and Science UniversityInventors: Ashish Kumar Pathak, Corinne E. Augelli-Szafran, Atefeh Garzan, Daniel Streblow, Nicole Haese
-
Patent number: 11181599Abstract: Methods, computer-readable storage devices, and systems are described for reducing movement of a patient undergoing a magnetic resonance imaging (MRI) scan by aligning MRI data, the method implemented on a Framewise Integrated Real-time MRI Monitoring (“FIRMM”) computing device including at least one processor in communication with at least one memory device. Aspects of the method comprise receiving a data frame from the MRI system, aligning the received data frame to a preceding data frame, calculating motion of a body part between the received data frame and the preceding data frame, calculating total frame displacement, and excluding data frames with a cutoff above a pre-identified threshold of the total frame displacement.Type: GrantFiled: March 8, 2018Date of Patent: November 23, 2021Assignees: Washington University, Oregon Health and Science UniversityInventors: Nico Dosenbach, Jonathan Koller, Andrew Van, Abraham Snyder, Amy Mirro, Damien Fair, Eric Earl, Rachel Klein, Oscar Miranda Dominguez, Anders Perrone
-
Patent number: 11091775Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: June 21, 2017Date of Patent: August 17, 2021Assignees: Oregon Health and Science University, International AIDS Vaccine Initative, Inc.Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
-
Publication number: 20210046018Abstract: The present disclosure provides ophthalmic compositions containing resveratrol. Also provided are methods of using ophthalmic resveratrol compositions to treat acute ocular pain, chronic ocular pain, dry eye disease, and/or photophobia.Type: ApplicationFiled: August 13, 2020Publication date: February 18, 2021Applicants: TED'S BRAIN SCIENCE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, OREGON HEALTH AND SCIENCE UNIVERSITYInventors: SUE A. AICHER, GREGORY O. DUSSOR, THEODORE J. PRICE, DENNIS I. ROBBINS, DAVID H. HITT, II, DAVID H. HITT, III
-
Patent number: 10607717Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.Type: GrantFiled: November 5, 2014Date of Patent: March 31, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health and Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HFInventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
-
Patent number: 10517494Abstract: A method and system for determining a patient's risk of ventricular tachycardia are disclosed. The method includes receiving ECG signals from a patient and filtering the collected ECG signals to generate filtered ECG signals. The method further includes identifying a heart vector from the filtered ECG signals, and measuring a velocity of the heart vector movement. A change in curvature of the identified heart vector movement is quantified and a risk of ventricular tachycardia is determined based at least on the measured velocity and the quantified change in curvature of the identified heart vector movement.Type: GrantFiled: November 13, 2015Date of Patent: December 31, 2019Assignees: Beth Israel Deaconess Medical Center, Inc., Johns Hopkins University, Oregon Health and Science UniversityInventors: Larisa G. Tereshchenko, Mark E. Josephson
-
Publication number: 20190153539Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.Type: ApplicationFiled: April 20, 2017Publication date: May 23, 2019Applicants: The United States of America, as represented by the secretary, Dep. of Health and Human Service, British Columbia Cancer Agency Branch, Julius-Maximilians - University of Würzburg, Oregon Health and Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, Board of Regents of the University of Nebraska, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and ResearchInventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
-
Patent number: 10143740Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.Type: GrantFiled: May 5, 2014Date of Patent: December 4, 2018Assignee: Oregon Health and Science UniversityInventors: Mark K. Slifka, Shirley Villadiego, Erika Hammarlund, Paul Yoshihara
-
Patent number: 10078091Abstract: A method, a labeling reagent, sets of labeling reagents, and labeling techniques are provided for the analysis of ketosterol biomarkers such as bile acid precursors from human plasma, serum or whole blood. This method is used for new born screening for Cerebrotendinous Xanthomatosis (CTX). Methods for labeling, analyzing, and quantifying ketosterol biomarkers are also disclosed as are methods that also use mass spectrometry.Type: GrantFiled: May 17, 2013Date of Patent: September 18, 2018Assignees: DH Technologies Development Pte. Ltd., Oregon Health and Science UniversityInventors: Andrea DeBarber, Subhasish Purkayastha, Robert D. Steiner, Michal Weinstock
-
Patent number: 10023538Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: GrantFiled: February 23, 2017Date of Patent: July 17, 2018Assignees: The United States of America as represented by the Department of Veterans Affairs, Oregon Health and Science UniversityInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Patent number: 10001635Abstract: One embodiment of techniques for confocal microscopy includes illuminating a spot on a surface of a biological sample. A first emission intensity from the spot is detected in a first range of optical properties; and a second emission intensity in a second ranges A pixel that corresponds to the spot is colored using a linear combination of the first and second emission intensities. Sometimes, the pixel is colored to approximate a color produced by histology. In some embodiments, a surface of a sample is contacted with a solution of a nucleus dye. Then, a spot is illuminated with a laser beam of wavelength about 488 nanometers (nm). Fluorescence emission intensity is detected above about 500 nm. Sometimes, a certain illumination correction is applied. In some embodiments, a sample holder that compresses a sample is removable from a stage that is fixed with respect to a focal plane of the microscope.Type: GrantFiled: September 28, 2015Date of Patent: June 19, 2018Assignees: Sloan Kettering Institute for Cancer Research, Oregon Health and Science UniversityInventor: Daniel S. Gareau
-
Patent number: 9962407Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: November 9, 2006Date of Patent: May 8, 2018Assignees: Athersys, Inc., Oregon Health and Science UniversityInventors: Robert Deans, Wouter Van't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
-
Publication number: 20180055881Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: November 6, 2017Publication date: March 1, 2018Applicants: ATHERSYS, INC., OREGON HEALTH AND SCIENCE UNIVERSITYInventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Patent number: 9808485Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: January 6, 2012Date of Patent: November 7, 2017Assignees: Athersys, Inc., Oregon Health And Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Publication number: 20170146517Abstract: Mutant mono ADP-ribose-polymerases (mono-PARP) proteins and small molecule compound substrates specific for the mutant mono-PARP proteins as well as methods of using these compositions to identify protein targets of the mono-PARPs and to screen for antagonists of the mono-PARPs are described.Type: ApplicationFiled: November 18, 2016Publication date: May 25, 2017Applicant: OREGON HEALTH AND SCIENCE UNIVERSITYInventors: Michael Cohen, Ian Carter-O'Connell, Rory Morgan, Haihong Jin
-
Patent number: 9554783Abstract: In one embodiment, a device for closing or occluding ASDs and PFOs, or other bodily passageways, includes a circumferential frame, a sheet of biocompatible material attached to the frame, and at least one anchor attached to the sheet of biocompatible material. In another embodiment, the closure device includes a circumferential frame, at least one crossbar extending across and attached to the frame, at least one anchor connected to at least one crossbar; and at least one sheet of biocompatible material (such as ECM material) attached to the frame. The anchor includes at least one grasping member having a structure, such as a wired loop, which is configured for releasable attachment to a delivery release member, which facilitates delivery of a closure device collapsibly disposed in a delivery catheter. Alternatively, one or more anchor end pairs may be connected to a delivery bar enhancing delivery and retrieval of the device.Type: GrantFiled: July 31, 2009Date of Patent: January 31, 2017Assignees: COOK MEDICAL TECHNOLOGIES LLC, OREGON HEALTH AND SCIENCE UNIVERSITYInventors: Dusan Pavcnik, Kurt J. Tekulve